Selected research
Industry Research
Blood-derived Products Industry Research Report 2026
Market perspective
The global Blood-derived Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Blood-derived Products is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Blood-derived Products is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Blood-derived Products is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Blood-derived Products include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, Shuanglin Bio, Shanghai RAAS, Hualan Bio, Boya Bio and CBPO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Blood-derived Products market in terms of revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Blood-derived Products Market by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
Shuanglin Bio
Shanghai RAAS
Hualan Bio
Boya Bio
CBPO
Octapharma
LFB Group
Kedrion
Grifols
CSL
Blood-derived Products Segment by Type
Coagulation Factors
Immunoglobulins
Albumin
Others
Blood-derived Products Segment by Application
Therapeutics
Excipient
Other
Blood-derived Products Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood-derived Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood-derived Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood-derived Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Blood-derived Products manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Blood-derived Products by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Blood-derived Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Coagulation Factors
- Immunoglobulins
- Albumin
- Others
Applications
- Therapeutics
- Excipient
- Other
Companies covered
- Yuanda Shuyang
- Takeda
- Weiguang Bio
- Tiantan Bio
- Shuanglin Bio
- Shanghai RAAS
- Hualan Bio
- Boya Bio
- CBPO
- Octapharma
- LFB Group
- Kedrion
- Grifols
- CSL
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Blood-derived Products Market Size (2021-2032)
- 2.2.2 Global Blood-derived Products Sales (2021-2032)
- 2.2.3 Global Blood-derived Products Market Average Price (2021-2032)
- 2.3 Blood-derived Products by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Coagulation Factors
- 2.3.3 Immunoglobulins
- 2.3.4 Albumin
- 2.3.5 Others
- 2.4 Blood-derived Products by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Therapeutics
- 2.4.3 Excipient
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Blood-derived Products Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Blood-derived Products Sales (t) of Manufacturers (2021-2026)
- 3.3 Global Blood-derived Products Revenue of Manufacturers (2021-2026)
- 3.4 Global Blood-derived Products Average Price by Manufacturers (2021-2026)
- 3.5 Global Blood-derived Products Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Blood-derived Products, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Blood-derived Products, Product Type & Application
- 3.8 Global Manufacturers of Blood-derived Products, Established Date
- 3.9 Global Blood-derived Products Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yuanda Shuyang
- 4.1.1 Yuanda Shuyang Company Information
- 4.1.2 Yuanda Shuyang Business Overview
- 4.1.3 Yuanda Shuyang Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yuanda Shuyang Blood-derived Products Product Portfolio
- 4.1.5 Yuanda Shuyang Recent Developments
- 4.2 Takeda
- 4.2.1 Takeda Company Information
- 4.2.2 Takeda Business Overview
- 4.2.3 Takeda Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Takeda Blood-derived Products Product Portfolio
- 4.2.5 Takeda Recent Developments
- 4.3 Weiguang Bio
- 4.3.1 Weiguang Bio Company Information
- 4.3.2 Weiguang Bio Business Overview
- 4.3.3 Weiguang Bio Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Weiguang Bio Blood-derived Products Product Portfolio
- 4.3.5 Weiguang Bio Recent Developments
- 4.4 Tiantan Bio
- 4.4.1 Tiantan Bio Company Information
- 4.4.2 Tiantan Bio Business Overview
- 4.4.3 Tiantan Bio Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Tiantan Bio Blood-derived Products Product Portfolio
- 4.4.5 Tiantan Bio Recent Developments
- 4.5 Shuanglin Bio
- 4.5.1 Shuanglin Bio Company Information
- 4.5.2 Shuanglin Bio Business Overview
- 4.5.3 Shuanglin Bio Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Shuanglin Bio Blood-derived Products Product Portfolio
- 4.5.5 Shuanglin Bio Recent Developments
- 4.6 Shanghai RAAS
- 4.6.1 Shanghai RAAS Company Information
- 4.6.2 Shanghai RAAS Business Overview
- 4.6.3 Shanghai RAAS Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shanghai RAAS Blood-derived Products Product Portfolio
- 4.6.5 Shanghai RAAS Recent Developments
- 4.7 Hualan Bio
- 4.7.1 Hualan Bio Company Information
- 4.7.2 Hualan Bio Business Overview
- 4.7.3 Hualan Bio Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hualan Bio Blood-derived Products Product Portfolio
- 4.7.5 Hualan Bio Recent Developments
- 4.8 Boya Bio
- 4.8.1 Boya Bio Company Information
- 4.8.2 Boya Bio Business Overview
- 4.8.3 Boya Bio Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Boya Bio Blood-derived Products Product Portfolio
- 4.8.5 Boya Bio Recent Developments
- 4.9 CBPO
- 4.9.1 CBPO Company Information
- 4.9.2 CBPO Business Overview
- 4.9.3 CBPO Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CBPO Blood-derived Products Product Portfolio
- 4.9.5 CBPO Recent Developments
- 4.10 Octapharma
- 4.10.1 Octapharma Company Information
- 4.10.2 Octapharma Business Overview
- 4.10.3 Octapharma Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Octapharma Blood-derived Products Product Portfolio
- 4.10.5 Octapharma Recent Developments
- 4.11 LFB Group
- 4.11.1 LFB Group Company Information
- 4.11.2 LFB Group Business Overview
- 4.11.3 LFB Group Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 LFB Group Blood-derived Products Product Portfolio
- 4.11.5 LFB Group Recent Developments
- 4.12 Kedrion
- 4.12.1 Kedrion Company Information
- 4.12.2 Kedrion Business Overview
- 4.12.3 Kedrion Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Kedrion Blood-derived Products Product Portfolio
- 4.12.5 Kedrion Recent Developments
- 4.13 Grifols
- 4.13.1 Grifols Company Information
- 4.13.2 Grifols Business Overview
- 4.13.3 Grifols Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Grifols Blood-derived Products Product Portfolio
- 4.13.5 Grifols Recent Developments
- 4.14 CSL
- 4.14.1 CSL Company Information
- 4.14.2 CSL Business Overview
- 4.14.3 CSL Blood-derived Products Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 CSL Blood-derived Products Product Portfolio
- 4.14.5 CSL Recent Developments
5 Global Blood-derived Products Market Scenario by Region
- 5.1 Global Blood-derived Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Blood-derived Products Sales by Region: 2021-2032
- 5.2.1 Global Blood-derived Products Sales by Region: 2021-2026
- 5.2.2 Global Blood-derived Products Sales by Region: 2027-2032
- 5.3 Global Blood-derived Products Revenue by Region: 2021-2032
- 5.3.1 Global Blood-derived Products Revenue by Region: 2021-2026
- 5.3.2 Global Blood-derived Products Revenue by Region: 2027-2032
- 5.4 North America Blood-derived Products Market Facts & Figures by Country
- 5.4.1 North America Blood-derived Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Blood-derived Products Sales by Country (2021-2032)
- 5.4.3 North America Blood-derived Products Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Blood-derived Products Market Facts & Figures by Country
- 5.5.1 Europe Blood-derived Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Blood-derived Products Sales by Country (2021-2032)
- 5.5.3 Europe Blood-derived Products Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Blood-derived Products Market Facts & Figures by Country
- 5.6.1 Asia Pacific Blood-derived Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Blood-derived Products Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Blood-derived Products Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Blood-derived Products Market Facts & Figures by Country
- 5.7.1 South America Blood-derived Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Blood-derived Products Sales by Country (2021-2032)
- 5.7.3 South America Blood-derived Products Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Blood-derived Products Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Blood-derived Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Blood-derived Products Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Blood-derived Products Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Blood-derived Products Sales by Type (2021-2032)
- 6.1.1 Global Blood-derived Products Sales by Type (2021-2032) & (t)
- 6.1.2 Global Blood-derived Products Sales Market Share by Type (2021-2032)
- 6.2 Global Blood-derived Products Revenue by Type (2021-2032)
- 6.2.1 Global Blood-derived Products Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Blood-derived Products Revenue Market Share by Type (2021-2032)
- 6.3 Global Blood-derived Products Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Blood-derived Products Sales by Application (2021-2032)
- 7.1.1 Global Blood-derived Products Sales by Application (2021-2032) & (t)
- 7.1.2 Global Blood-derived Products Sales Market Share by Application (2021-2032)
- 7.2 Global Blood-derived Products Revenue by Application (2021-2032)
- 7.2.1 Global Blood-derived Products Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Blood-derived Products Revenue Market Share by Application (2021-2032)
- 7.3 Global Blood-derived Products Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Blood-derived Products Value Chain Analysis
- 8.1.1 Blood-derived Products Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Blood-derived Products Production Mode & Process
- 8.2 Blood-derived Products Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Blood-derived Products Distributors
- 8.2.3 Blood-derived Products Customers
9 Global Blood-derived Products Analyzing Market Dynamics
- 9.1 Blood-derived Products Industry Trends
- 9.2 Blood-derived Products Industry Drivers
- 9.3 Blood-derived Products Industry Opportunities and Challenges
- 9.4 Blood-derived Products Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst